Browsing Tag
immuno-oncology
35 posts
Xencor stock skyrockets 26% overnight after breakthrough in cancer research
Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by…
Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a…
GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab)…
Affimed N.V. reports promising results from AFM24-102 trial in NSCLC
Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, has released compelling clinical data from its ongoing AFM24-102 study,…
FibroGen and Regeneron Pharmaceuticals forge clinical trial collaboration for cancer treatment
FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate…
10x Genomics introduces new solutions for single cell and spatial biology research
10x Genomics, Inc. (Nasdaq: TXG), a pioneering company in single cell and spatial biology, has announced the commercial…
FDA approves BeiGene’s TEVIMBRA for esophageal cancer treatment
In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally…
Sanofi signs $1.45bn deal to acquire Kymab, expanding its immune-therapy pipeline
In a significant move to bolster its immuno-oncology and immune-mediated disease portfolio, Sanofi has acquired Kymab, a UK-based…
EMD Serono facility expansion in Massachusetts set to advance immuno-oncology research
German pharmaceutical giant Merck KGaA has announced a significant investment of $70 million to expand its EMD Serono…
Astellas Pharma acquires Potenza Therapeutics in $404.7m deal
Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued…